Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Lobaplatin-TACE Combined with Radioactive 125I Seed Implantation for Treatment of Primary Hepatocellular Carcinoma

  • Peng, Sheng (Department of Medical Imaging and Minimally Invasive Interventional Center, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine) ;
  • Yang, Qiu-Xia (Department of Medical Imaging and Minimally Invasive Interventional Center, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine) ;
  • Zhang, Tao (Department of Medical Imaging and Minimally Invasive Interventional Center, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine) ;
  • Lu, Ming-Jian (Department of Medical Imaging and Minimally Invasive Interventional Center, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine) ;
  • Yang, Guang (Department of Medical Imaging and Minimally Invasive Interventional Center, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine) ;
  • Liu, Zhen-Yin (Department of Medical Imaging and Minimally Invasive Interventional Center, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine) ;
  • Zhang, Rong (Department of Medical Imaging and Minimally Invasive Interventional Center, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine) ;
  • Zhang, Fu-Jun (Department of Medical Imaging and Minimally Invasive Interventional Center, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine)
  • Published : 2014.07.15
Download PDF
⟨ Previous Next ⟩

Abstract

Aim: To investigate the efficacy and safety of lobaplatin-transcatheter arterial chemoembolization (TACE) combined with radioactive $^{125}I$ seed implantation in treatment of primary hepatocellular carcinoma (HCC). Methods: 75 patients with primary HCC were enrolled in the study, among them 43 receiving lobaplatin-TACE (TACE group) and 32 lobaplatin-TACE combined with $^{125}I$ seed implantation (TACE+$^{125}I$ group). After treatment, the local remission rates and postoperative complications of two groups were compared using the Pearson Chi-square test. Overall survival in the two groups was calculated using Kaplan-Meier survival curves and the differences were tested using Log-rank test. Results: There were 7 cases of complete response (CR), 13 of partial response (PR), 6 of stable disease (SD) and 17 of progressive disease (PD) in the TACE group, with 13 cases of CR, 9 of PR, 5 of SD and 5 of PD in the TACE+$^{125}I$ group. The disease control rates of TACE and TACE+$^{125}I$ group were 60.5% (26/43) and 84.4% (27/32), respectively, with a significant difference between them (P < 0.05). The survival rates at 6, 12 and 18 months in the TACE group were 100.0%, 81.8% and 50.0%, respectively, and those in TACE+$^{125}I$ group were 100.0%, 93.8% and 65.6%. The mean survival times in the TACE and TACE+$^{125}I$ groups were 19.5 and 22.9 months, respectively. There was a significant difference in the overall survival rate between two groups (P < 0.05). No serious complications were encountered in either group. Conclusion: Lobaplatin-TACE combined with $^{125}I$ seed implantation is favorable and safe for treatment of primary HCC.

Keywords

References

  1. AEterna Laboratories (2003). Lobaplatin: D 19466. Drugs R D, 4, 369-72. https://doi.org/10.2165/00126839-200304060-00008
  2. Bruix J, Sherman M (2011). Management of hepatocellular carcinoma: an update. Hepatology, 53, 1020-2. https://doi.org/10.1002/hep.24199
  3. Cha CH, Saif MW, Yamane BH, et al (2010). Hepatocellular carcinoma: current management. Curr Probl Surg, 47, 10-67. https://doi.org/10.1067/j.cpsurg.2009.09.003
  4. Cheng AL, Kang YK, Chen Z, et al (2009). Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol, 10, 25-34. https://doi.org/10.1016/S1470-2045(08)70285-7
  5. Dawson LA, Lawrence TS (2004). The role of radiotherapy in the treatment of liver metastases. Cancer J, 10, 139-44. https://doi.org/10.1097/00130404-200403000-00009
  6. Eisenhauer EA, Therasse P, Bogaerts J, et al (2009). New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer, 45, 228-47. https://doi.org/10.1016/j.ejca.2008.10.026
  7. Forner A, Llovet JM, Bruix J (2012). Hepatocellular carcinoma. Lancet, 379, 1245-55. https://doi.org/10.1016/S0140-6736(11)61347-0
  8. Gabizon A, Peretz T, Sulkes A, et al (1989). Systemic administration of doxorubicin-containing liposomes in cancer patients: a phase I study. Eur J Cancer Clin Oncol, 25, 1795-803. https://doi.org/10.1016/0277-5379(89)90350-7
  9. Gietema JA, de Vries EG, Sleijfer DT, et al (1993). A phase I study of 1, 2-diamminomethyl-cyclobutane-platinum (II)-lactate (D-19466; lobaplatin) administered daily for 5 days. Br J Cancer, 67, 396-401. https://doi.org/10.1038/bjc.1993.73
  10. Kim HC, Lee JH, Chung JW, et al (2013). Transarterial chemoembolization with additional cisplatin infusion for hepatocellular carcinoma invading the hepatic vein. J Vasc Interv Radiol, 24, 274-83. https://doi.org/10.1016/j.jvir.2012.11.002
  11. Li C, Zhang F, Zhang W, et al (2010). Feasibility of (125)I brachytherapy combined with sorafenib treatment in patients with multiple lung metastases after liver transplantation for hepatocellular carcinoma. J Cancer Res Clin Oncol, 136, 1633-40. https://doi.org/10.1007/s00432-010-0821-z
  12. Llovet JM, Bruix J (2003). Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology, 37, 429-42. https://doi.org/10.1053/jhep.2003.50047
  13. Llovet JM, Bustamante J, Castells A, et al (1999). Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials. Hepatology, 29, 62-7. https://doi.org/10.1002/hep.510290145
  14. Ma TC, Shao HB, Xu Y, et al (2013). Three treatment methods via the hepatic artery for hepatocellular carcinoma - a retrospective study. Asian Pac J Cancer Prev, 14, 2491-4. https://doi.org/10.7314/APJCP.2013.14.4.2491
  15. Marelli L, Stigliano R, Triantos C, et al (2007). Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies. Cardiovasc Intervent Radiol, 30, 6-25. https://doi.org/10.1007/s00270-006-0062-3
  16. Martin R, Geller D, Espat J, et al (2012). Safety and efficacy of trans arterial chemoembolization with drug-eluting beads in hepatocellular cancer: a systematic review. Hepatogastroenterology, 59, 255-60.
  17. Martinez-Monge R, Nag S, Nieroda CA, et al (1999). Iodine-125 brachytherapy in the treatment of colorectal adenocarcinoma metastatic to the liver. Cancer, 85, 1218-25. https://doi.org/10.1002/(SICI)1097-0142(19990315)85:6<1218::AID-CNCR2>3.0.CO;2-F
  18. McKeage MJ (2001). Lobaplatin: a new antitumour platinum drug. Expert Opin Investig Drugs, 10, 119-28. https://doi.org/10.1517/13543784.10.1.119
  19. Meng N, Jiang YL, Wang JJ, et al (2012). Permanent implantation of iodine-125 seeds as a salvage therapy for recurrent head and neck carcinoma after radiotherapy. Cancer Invest, 30, 236-42. https://doi.org/10.3109/07357907.2012.654869
  20. Nakamura H, Yasui Y, Saito N, et al (2006). DNA repair defect in AT cells and their hypersensitivity to low-dose-rate radiation. Radiat Res, 165, 277-82. https://doi.org/10.1667/RR3519.1
  21. Sherman M (2010). Epidemiology of hepatocellular carcinoma. Oncology, 78, 7-10. https://doi.org/10.1159/000315223
  22. Shi M, Lu LG, Fang WQ, et al (2013). Roles played by chemolipiodolization and embolization in chemoembolization for hepatocellular carcinoma: single-blind, randomized trial. J Natl Cancer Inst, 105, 59-68. https://doi.org/10.1093/jnci/djs464
  23. Voegeli R, Schumacher W, Engel J, et al (1990). D-19466, a new cyclobutane-platinum complex with antitumor activity. J Cancer Res Clin Oncol, 116, 439-42. https://doi.org/10.1007/BF01612990
  24. Wang KX, Jin ZD, Du YQ, et al (2012). EUS-guided celiac ganglion irradiation with iodine-125 seeds for pain control in pancreatic carcinoma: a prospective pilot study. Gastrointest Endosc, 76, 945-52. https://doi.org/10.1016/j.gie.2012.05.032
  25. Xue TC, Xie XY, Zhang L, et al (2013). Transarterial chemoembolization for hepatocellular carcinoma with portal vein tumor thrombus: a meta-analysis. BMC Gastroenterol, 13, 60. https://doi.org/10.1186/1471-230X-13-60
  26. Yang CF, Ho YJ (1992). Transcatheter arterial chemoembolization for hepatocellular carcinoma. Cancer Chemother Pharmacol, 31, S86-8. https://doi.org/10.1007/BF00687113
  27. Zhang FJ, Li CX, Wu PH, et al (2007). Radioactive seed 125I implantation in treating recurrence and metastasis after liver transplantation in hepatoma. Chin Med J, 87, 956-9 (In Chiese).
  28. Zhang FJ, Li CX, Zhang L, et al (2009). Short- to mid-term evaluation of CT-guided 125I brachytherapy on intra-hepatic recurrent tumors and/or extra-hepatic metastases after liver transplantation for hepatocellular carcinoma. Cancer Biol Ther, 8, 585-90. https://doi.org/10.4161/cbt.8.7.7902
  29. Zhang FJ, Wu PH, Zhao M, et al (2006). CT guided radioactive seed 125I implantation in treatment of pancreatic cancer. Chin Med J, 86, 223-7 (in Chinese).
  30. Zhang L, Mu W, Hu CF, et al (2010). Treatment of portal vein tumor thrombus using 125Iodine seed implantation brachytherapy. World J Gastroenterol, 16, 4876-9. https://doi.org/10.3748/wjg.v16.i38.4876
  31. Zhao M, Wang JP, Wu PH, et al (2010). Comparative analysis of TACE alone or plus RFA in the treatment of 167 cases of intermediate and advanced staged primary hepatocellular carcinoma. Chin Med J, 90, 2916-21 (in Chinese).
  32. Zhou B, Shan H, Zhu KS, et al (2010). Chemoembolization with lobaplatin mixed with iodized oil for unresectable recurrent hepatocellular carcinoma after orthotopic liver transplantation. J Vasc Interv Radiol, 21, 333-8. https://doi.org/10.1016/j.jvir.2009.11.006

Cited by

  1. Asparagus Polysaccharide and Gum with Hepatic Artery Embolization Induces Tumor Growth and Inhibits Angiogenesis in an Orthotopic Hepatocellular Carcinoma Model vol.15, pp.24, 2015, https://doi.org/10.7314/APJCP.2014.15.24.10949
  2. Application and Progress of the Stents Used in the Therapy of Malignant Biliary Obstruction vol.06, pp.01, 2016, https://doi.org/10.12677/ACM.2016.61011
  3. Iodine-125 Brachytherapy Prophylaxis after Radiofrequency Ablation Cannot Benefit Patients in High Risk of Locoregional Hepatocellular Carcinoma Recurrence vol.7, pp.1, 2017, https://doi.org/10.1038/s41598-017-03831-5
  4. I Radioactive Particle Implantation and Cytokine-Induced Killer Cell Therapy on Xenograft Hepatocellular Carcinoma in a Mouse Model pp.1533-0338, 2017, https://doi.org/10.1177/1533034617732204